Finding solutions to unmet needs in medical dermatology. 

Verrica is developing innovative therapies for common skin diseases.


Verrica submits a New Drug Application for VP-102, a proprietary topical therapy, for the treatment of molluscum contagiosum

Press Release

At Verrica, innovation is in our DNA.

Verrica Pharmaceuticals Inc. is a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases. We seek to understand the patient journey and the healthcare provider landscape when developing our clinical programs, with the goal of delivering treatment solutions for millions of underserved patients.

Headquartered in West Chester, Pennsylvania, Verrica was founded in 2013. We are led by a seasoned management team with extensive pharmaceutical industry experience ranging from drug development through commercialization and collectively launched more than 50 products. Our lead product candidate, VP-102, is a proprietary drug-device combination of our novel topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, clinically administered through our single-use precision applicator. We are initially developing VP-102 for the treatment of molluscum contagiosum, a highly contagious viral skin infection affecting approximately six million people, primarily children, in the United States, and common warts.  There are currently no products approved by the U.S. Food and Drug Administration nor is there an established standard of care for either of these diseases, resulting in significant undertreated populations in two of the largest unmet needs in dermatology.